Diagnostic, Risk Stratification and Prognostic Value of Novel Biomarkers in Patients With Heart Failure
Diagnostic, Risk Stratification and Prognostic Value of Novel Biomarkers in Patients With Heart Failure: DRAGON-HF Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Dachun Xu, Ph.D
- Phone Number: 0086-18917684045
- Email: xdc77@tongji.edu.cn
Study Contact Backup
- Name: Yuxi Sun, Ph.D
- Phone Number: 0086-15216718171
- Email: sunyuxitj10h@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200072
- Recruiting
- Shanghai Tenth people's hospital, Tongji university
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age > 18 years of age
- Symptomatic (NYHA class II-IV) heart failure (as diagnosed by clinician, radiographic images, or abnormal natriuretic peptide level)
- Hospital admission, Emergency Department visit, or outpatient diuretic escalation of therapy for destabilized HF at least once in the 6 months prior to enrollment
Exclusion Criteria:
- Life expectancy <1 year due to causes other than HF such as advanced cancer
- Cardiac transplantation or revascularization indicated or expected within 6 months
- Severe obstructive or restrictive pulmonary disease, defined as a forced expiratory volume in 1 sec <1 L (when diagnosed as standard of care)
- Subject unable or unwilling to provide written informed consent
- Coronary revascularization (percutaneous coronary intervention or bypass surgery) within the previous 3 months
- Progressive neurological disease
- Pregnancy
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
healthy control
|
|
|
Patients with heart failure
Patients with heart failure (HF) who are followed in the hospital or clinic setting, with optimization of medical therapy and blood collection.
|
Participants will have serial blood collection on medical therapy for heart failure
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with cardiaovascular death after 5-year follow up
Time Frame: 5 years
|
The cardiovascular mortality after 5-year follow up will be assessed to detect prognostic values of circulating biomarkers
|
5 years
|
|
Time to decompensated heart failure (HF) requiring in-patient admission or ER visit or IV diuretic therapy in the outpatient realm
Time Frame: 5 years
|
New onset of classic symptoms and signs of destabilized HF, including lower extremity edema, jugular venous distension, bibasilar crackles, orthopnea and paroxysmal nocturnal dyspnea.
|
5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of new biomarker with NT-ProBNP on diagnostic value in patients with heart failure
Time Frame: 1 year
|
Compare the sensitivity and specificity of new biomarker with NT-ProBNP to assess the accuracy of diagnostic value in discriminating heart failure from non-heart failure participants.
|
1 year
|
|
Change From Baseline in left ventricular ejection fraction
Time Frame: 5 years
|
Assess the change in left ventricular ejection fraction at the end of 5-year follow up.
|
5 years
|
|
Change From Baseline in left ventricular end-systolic volume
Time Frame: 5 years
|
Assess the change in left ventricular end-systolic volume at the end of 5-year follow up.
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Dachun Xu, Ph.D, Shanghai 10th People's Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DRAGON-HF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.